Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.ASN.0000089026.28617.33PMID 14514739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

  2002cited by this paper
• Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease

  2002cited by this paper
• Neurohormonal activation in heart failure after acute myocardial infarction treated with beta‐receptor antagonists

  2002cited by this paper
• Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease

  2002cited by this paper
• Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients.

  2002cited by this paper
• Plasma Neuropeptide Y Concentrations in Patients on Hemodialysis

  2002cited by this paper
• Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

  2001cited by this paper
• Predictions for future growth of ESRD prevalence

  2000cited by this paper
• C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.

  2000cited by this paper
• Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

  1999cited by this paper
• Sympathetic activation in the pathogenesis of hypertension and progression of organ damage.

  1999cited by this paper
• Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

  1998cited by this paper
• Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip.

  1998cited by this paper
• Is neuropeptide Y a contributor to volume-induced hypertension?

  1998cited by this paper
• Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

  1998cited by this paper
• Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure.

  1997influential reference
• Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans.

  1997cited by this paper
• Neuropeptide Y family of hormones: receptor subtypes and antagonists.

  1997cited by this paper
• The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease.

  1996cited by this paper
• Metabolism and functions of neuropeptide Y

  1996cited by this paper
• Treatment in hypertensive cardiac hypertrophy, I. Neuropeptide Y and beta-adrenoceptors.

  1995cited by this paper
• Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11.

  1994cited by this paper
• Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction.

  1994cited by this paper
• Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes.

  1994cited by this paper
• Changes in plasma levels of vasoactive substances during routine acetate and bicarbonate hemodialysis.

  1994cited by this paper
• Neuropeptide Y and cardiovascular regulation.

  1993cited by this paper
• Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma.

  1992cited by this paper
• Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment.

  1992cited by this paper
• NEUROENDOCRINOLOGY OF CHRONIC RENAL FAILURE AND RENAL TRANSPLANTATION

  1991cited by this paper
• Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes.

  1991cited by this paper
• Elevation of plasma neuropeptide Y‐like immunoreactivity and noradrenaline during myocardial ischaemia in man

  1990cited by this paper
• Regulation of the Hypothalamo‐Pituitary Axis by Neuropeptide Y

  1990cited by this paper
• Neuropeptide Y-like immunoreactivity in relation to the distribution of sympathetic nerve fibers in the heart conduction system.

  1989cited by this paper
• Elevation of plasma neuropeptide Y levels in congestive heart failure.

  1989cited by this paper
• Role of neuropeptide Y (NPY) in cardiovascular responses to stress

  1988cited by this paper
• Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man.

  1987cited by this paper
• Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure.

  1987cited by this paper

• Serum Prealbumin Levels and Risks of Adverse Clinical Outcomes After Ischemic Stroke

  2024cites this paper
• Plasma neuropeptide Y levels and adverse clinical outcomes after acute ischaemic stroke

  2024cites this paper
• Association of stress hormones and the risk of cardiovascular diseases systematic review and meta-analysis

  2024cites this paper
• Association between Ambient Illumination and Cognitive Impairment: A Population-Based Study of Older.

  2023cites this paper
• A genetically encoded tool for reconstituting synthetic modulatory neurotransmission and reconnect neural circuits in vivo

  2021cites this paper
• Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges

  2021cites this paper
• Angiopoietin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus

  2020cites this paper
• Assessment of the Association between Neuropeptide Y and Chronic Kidney Disease Progression

  2020influential citation
• Immune Dysfunction in Uremia 2020

  2020cites this paper
• Mechanisms of cognitive dysfunction in CKD

  2020cites this paper
• Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study.

  2019cites this paper
• Neuropeptide Y and chronic kidney disease progression: a cohort study.

  2018cites this paper
• Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update

  2018cites this paper
• The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study)

  2017cites this paper
• The systemic nature of CKD

  2017cites this paper
• Chronic Kidney Disease As a Potential Indication for Renal Denervation

  2016cites this paper
• The peptidic middle molecules: is molecular weight doing the trick?

  2014cites this paper
• Lack of an Association between a Functional Polymorphism in the Neuropeptide Y Gene Promoter and the Presence of Coronary Artery Disease in an Iranian Population

  2014cites this paper
• Hunting the Risk NPY and ACE Polymorphisms as Predictors of Cardiovascular Diseases: Case Report and Review of the Literature

  2013cites this paper
• Chapter 4 – Uremic Toxicity

  2013cites this paper
• Vasopressin release is enhanced by the Hemocontrol biofeedback system and could contribute to better haemodynamic stability during haemodialysis

  2013cites this paper
• Temporal patterns in the pathophysiology of dialysis patients : an epidemiological approach

  2013cites this paper
• Anorexia and Appetite Stimulants in Chronic Kidney Disease

  2013cites this paper
• Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients.

  2012cites this paper
• Relation between trends in body temperature and outcome in incident hemodialysis patients.

  2012cites this paper
• Novel Approaches in Hypertension Treatment - Modulation of the Sympathetic Overactivity

  2011cites this paper
• Of Mice and Men: Neuropeptide Y and Its Receptors Are Associated with Atherosclerotic Lesion Burden and Vulnerability

  2011cites this paper
• Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

  2011cites this paper
• Mechanisms of altered regulation of food intake in chronic kidney disease.

  2011cites this paper
• Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients

  2010cites this paper
• Neuropeptide Y polymorphisms and ischemic stroke in Chinese population.

  2010cites this paper
• Wpływ neuropeptydu Y na regulację czynności układu krążenia

  2010cites this paper
• Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis

  2009cites this paper
• Why are chronic kidney disease patients anorexic and what can be done about it?

  2009cites this paper
• Uraemic toxins in chronic kidney disease

  2008cites this paper
• Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.

  2008cites this paper
• The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?

  2008cites this paper
• Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions.

  2008cites this paper
• Increased Plasma Neuropeptide Y Concentration in Elderly Subjects Zwiększone stężenie neuropeptydu Y w osoczu u osób w wieku podeszłym

  2008cites this paper
• NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sympathetic Overactivity—The Cinderella of Cardiovascular Risk Factors in Dialysis Patients

  2008cites this paper
• Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study.

  2008cites this paper
• Up-regulation of NPY gene expression in hypothalamus of rats with experimental chronic renal failure.

  2007cites this paper
• Uremic toxins in chronic renal failure.

  2007cites this paper
• Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?

  2007cites this paper
• Proteomics of Human Dialysate and Ultrafiltrate Fluids Yielded by Renal Replacement Therapy

  2007influential citation
• Are biomarkers useful for asses sing cardiovascular risk in patients with chronic kidney disease?

  2007cites this paper
• Pathophysiologie der Hypertonie: Was gibt es Neues?

  2006cites this paper
• Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.

  2006cites this paper
• [Pathophysiology of hypertension: what's new?].

  2006cites this paper
• Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats.

  2005cites this paper
• Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.

  2005cites this paper
• Chronic kidney disease as cause of cardiovascular morbidity and mortality.

  2005cites this paper
• Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases

  2005cites this paper
• Hormonal responses to fasting and refeeding in chronic renal failure patients.

  2005cites this paper
• Mineral metabolism Orchestrating the hormones of phosphate homeostasis

  2004cites this paper